Evidence map›Paper›PMID 39731163›Full record

ArticleClinical epigenetics2024

Correction: miR-29c plays a suppressive role in breast cancer by targeting the TIMP3/STAT1/ FOXO1 pathway.

Wan Li, Jie Yi, Xiangjin Zheng, Shiwei Liu, Weiqi Fu, Liwen Ren, Li Li, Dave S B Hoon, Jinhua Wang, Guanhua Du

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical epigenetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Wan Li *The State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing, China.
Jie Yi *Department of Clinical Laboratory, Peking Union Medical College Hospital, Beijing, 100730, China.
Xiangjin ZhengThe State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing, China.
Shiwei LiuDepartment of Endocrinology, Shanxi DAYI Hospital, Shanxi Medical University, Taiyuan, 030002, Shanxi, China.
Weiqi FuThe State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing, China.
Liwen RenThe State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing, China.
Li LiKey Laboratory of Drug Target Research and Drug Screen, Institute of Materia Medica, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, 100050, China.
Dave S B HoonDepartment of Translational Molecular Medicine, John Wayne Cancer Institute (JWCI) at Providence Saint John's Health Center, Santa Monica, CA, 90404, USA.
Jinhua WangThe State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing, China. wjh@imm.ac.cn.
Guanhua DuThe State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing, China. dugh@imm.ac.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39731163
PMCPMC11681663

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.